CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 155,963 enrolled
Drug / intervention
Amiloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05125237
NCT05125237N/ACompleted
CompareCT.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene

Brigham and Women's Hospital·observational·Posted Nov 18, 2021·Updated Nov 6, 2025

In Brief

An observational study evaluating Amiloride and Triamterene for Hypertension. Completed, enrolled 155,963 participants across 1 site.

Detailed Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Rutgers University, Johns Hopkins University

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 18, 2021
Enrollment StartOct 1, 2021
Primary CompletionJul 7, 2023
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.6 years ago

Interventions

Amiloridedrug

Amiloride claim is used as the exposure group.

Triamterenedrug

Triamterene claim is used as the reference group.